Recent advances in the discovery of 11β-HSD1 inhibitors

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 4, 2008, Pages 495-511

  Boyle, C D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

11 Hydroxysteroid dehydrogenase type 1; Glucocorticoids; Inhibitor; Metabolic syndrome; Obesity; Type 2 diabetes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; 2 PYRROLIDONE DERIVATIVE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ADAMANTANE DERIVATIVE; AMG 221; AMG 311; BICYCLO COMPOUND; BVT 14225; CARBENOXOLONE; CORTISONE; ENZYME INHIBITOR; FATTY ACID BINDING PROTEIN; GLYCYRRHETINIC ACID DERIVATIVE; HETEROCYCLIC COMPOUND; HYDROCORTISONE; INCB 13739; INCB 20817; METFORMIN; MIFEPRISTONE; NATURAL PRODUCT; PF 915275; PYRAZOLONE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; SULFONAMIDE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TROPANE DERIVATIVE; UNINDEXED DRUG;

BINDING AFFINITY; CATALYSIS; CLINICAL TRIAL; COFFEE; COGNITIVE DEFECT; DISEASE MODEL; DRUG EFFECT; DRUG SYNTHESIS; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENZYME INHIBITORS; GLUCOCORTICOIDS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46749139850     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Obesity and overweight. Fact sheet 311: World Health Organization, Geneva, Switzerland (2006). www.who.int/mediacentre/factsheets/fs311/en/ index.html
2. Diabetes. Fact sheet 312: World Health Organization, Geneva, Switzerland (2006). www.who.int/mediacentre/factsheets/fs312/en/index.html
3. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. J Am Med Assoc (2003) 289(1):76-79.
4. Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet (2005) 365(9468):1415-1428.
5. Matfin G: Challenges in developing drugs for the metabolic syndrome. Curr Diabetes Rep (2008) 8(1):31-36.
6. Walker BR: Cortisol - cause and cure for metabolic syndrome? Diabetes Med (2006) 23(12):1281-1288.
7. Stimson RH, Walker BR: Glucocorticoids and 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Minerva Endocrinol (2007) 32(3):141-159.
8. Hughes KA, Webster SP, Walker BR: 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Invest Drugs (2008) 17(4):481-496. •• A recent review of 11β-HSD1 inhibitors that includes a summary of preclinical and clinical results of advanced structural classes and their implications for the treatment of various aspects of metabolic syndrome. Several primary references on the biology of 11β-HSD1 inhibition are also included.
9. Wamil M, Seckl JR: Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Disc Today (2007) 12(13-14):504-520. •• A recent review of 11β-HSD1 inhibitors that includes a detailed summary of human studies of 11β-HSD1 inhibition and several primary references on the biology of 11β-HSD1 inhibition.
10. Barf T, Williams M: Recent progress in 11-β-hydroxysteroid dehydrogenase type 1 (11-β-HSD1) inhibitor development. Drugs Future (2006) 31(3):231-243.
11. Wang M: Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Invest Drugs (2006) 7(4):319-323.
12. Oppermann U: Type 1 11β-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases? Endocr Metab Immune Disord Drug Targets (2006) 6(3):259-269.
13. Wang M: Tissue-specific glucocorticoid excess in the metabolic syndrome: 11β-HSD1 as a therapeutic target. Drug Dev Res (2006) 67(7):567-569.
14. Boyle CD, Kowalski T, Zhang L: 11β-Hydroxysteroid dehydrogenase type 1 inhibitors. Annu Rep Med Chem (2006) 41:127-140. • Provides a summary of the background of 11β-HSD1 inhibition and the structural classes of 11β-HSD1 inhibitors that had been reported up to 2006. Several primary references on the biology of 11β-HSD1 inhibition are also included.
15. Atanasov AG, Odermatt A: Readjusting the glucocorticoid balance: An opportunity for modulators of 11β-hydroxysteroid dehydrogenase type 1 activity? Endocr Metab Immune Disord Drug Targets (2007) 7(2):125-140.
16. Newell-Price J, Bertagna X, Grossman AB, Nieman LK: Cushing's syndrome. Lancet (2006) 367(9522):1605-1617.
17. Chu JW, Matthias DF, Belanoff J, Schatzberg A, Hoffman AR, Feldman D: Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab (2001) 86(8):3568-3573.
18. Oppermann UC, Persson B, Jörnvall H: Function, gene organization and protein structures of 11β-hydroxysteroid dehydrogenase isoforms. Eur J Biochem (1997) 249(2):355-360.
19. Strain GW, Zumoff B, Strain JJ, Levin J, Fukushima DK: Cortisol production in obesity. Metabolism (1980) 29(10):980-985.
20. Monder C, Stewart PM, Lakshmi V, Valentino R, Burt D, Edwards CR: Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: In vivo and in vitro studies. Endocrinology (1989) 125(2):1046-1053.
21. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS: Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol (1994) 105(2):R11-R17.
22. Barf T, Vallgårda J, Emond R, Häggström C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L et al: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem (2002) 45(18):3813-3815. • Describes the discovery of the first potent and selective small-molecule 11β-HSD1 inhibitors BVT-14225 and BVT-2733.
23. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H et al: 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med (2005) 202(4):517-527. • Describes several rodent studies with the selective triazole 11β-HSD1 inhibitor from Merck. The in vivo results were the first to demonstrate a positive effect on atherosclerosis with a small-molecule 11β-HSD1 inhibitor. Further experiments with the triazole also demonstrated positive effects on the other components of metabolic syndrome.
24. Lamberts SW, Koper JW, de Jong FH: The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab (1991) 73(1):187-191.
25. Hale C, Véniant M, Wang Z, Chen M, McCormick J, Cupples R, Hickman D, Min X, Sudom A, Xu H, Matsumoto G et al: Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Chem Biol Drug Des (2008) 71(1):36-44. • Describes the full characterization of the selective small-molecule 11β-HSD1 inhibitor compound 2922 from Amgen, including a mouse model that demonstrated a lack of hypothalamic- pituitary-adrenal axis activation by compound 2922.
26. Walker BR: Glucocorticoids and cardiovascular disease. Eur J Endocrinol (2007) 157(5):545-559.
27. Holmes MC, Seckl JR: The role of 11β-hydroxysteroid dehydrogenases in the brain. Mol Cell Endocrinol (2006) 248 (1-2):9-14.
28. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR: 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA (2004) 101(17):6734-6739.
29. Chapman KE, Gilmour JS, Coutinho AE, Savill JS, Seckl JR: 11β-Hydroxysteroid dehydrogenase type 1 - a role in inflammation? Mol Cell Endocrinol (2006) 248(1-2):3-8.
30. Webster SP, Pallin TD: 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents. Expert Opin Ther Pat (2007) 17(12):1407-1422. • A recent and extensive 11β-HSD1 patent review covering the literature from 2006 to August 2007.
31. Fotsch C, Askew BC, Chen JJ: 11β-Hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases. Expert Opin Ther Pat (2005) 15(3):289-303. • The first extensive patent review of 11β-HSD1 inhibitors covering the literature up to 2005.
32. Su X, Vicker N, Lawrence H, Smith A, Purohit A, Reed MJ, Potter BV: Inhibition of human and rat 11β-hydroxysteroid dehydrogenase type 1 by 18β-glycyrrhetinic acid derivatives. J Steroid Biochem Mol Biol (2007) 104(3-5):312-320.
33. Atanasov AG, Dzyakanchuk AA, Schweizer RA, Nashev LG, Maurer EM, Odermatt A: Coffee inhibits the reactivation of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1: A glucocorticoid connection in the anti-diabetic action of coffee? FEBS Lett (2006) 580(17):4081-4085.
34. Morris DJ, Latif SA, Hardy MP, Brem AS: Endogenous inhibitors (GALFs) of 11β-hydroxysteroid dehydrogenase isoforms 1 and 2: Derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol (2007) 104(3-5):161-168.
35. AMG-211. Thomson Pharma Drug Report, Thomson Reuters - Scientific, London, UK (2008).
36. Su X, Vicker N, Ganeshapillai D, Smith A, Pirohit A, Reed MJ, Potter BVL: Benzothiazole derivatives as novel inhibitors of human 11β- hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol (2006) 248(1-2):214-217.
37. Xiang J, Ipek M, Suri V, Massefski W, Pan N, Ge T, Tam M, Xing Y, Tobin JF, Xu X, Tam S: Synthesis and biological evaluation of sulfonamidooxazoles and β-keto sulfones: Selective inhibitors of 11β-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett (2005) 15(11):2865-2869.
38. Yuan C, St Jean DJ Jr, Liu Q, Cai L, Li A, Han N, Moniz G, Askew B, Hungate RW, Johansson L, Tedenborg L et al: The discovery of 2-anilinothiazolones as 11β-HSD1 inhibitors. Bioorg Med Chem Lett (2007) 17(22):6056-6061.
39. St Jean DJ Jr, Yuan C, Bercot EA, Cupples R, Chen M, Fretland J, Hale C, Hungate RW, Komorowski R, Veniant M, Wang M et al: 2-( S)-Phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteroid dehydrogenase type 1. J Med Chem (2007) 50(3):429-432.
40. Sutin L, Andersson S, Bergquist L, Castro VM, Danielsson E, James S, Henriksson M, Johansson L, Kaiser C, Flyrén K, Williams M: Oxazolones as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett (2007) 17(17):4837-4840.
41. Rohde JJ, Pliushchev MA, Sorensen BK, Wodka D, Shuai Q, Wang J, Fung S, Monzon KM, Chiou WJ, Pan L, Deng X et al: Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11β-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem (2007) 50(1):149-164.
42. Sorensen B, Rohde J, Wang J, Fung S, Monzon K, Chiou W, Pan L, Deng X, Stolarik D, Frevert EU, Jacobson P et al: Adamantane 11-β-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction. Bioorg Med Chem Lett (2006) 16(23):5958-5962.
43. Yeh VS, Patel JR, Yong H, Kurukulasuriya R, Fung S, Monzon K, Chiou W, Wang J, Stolarik D, Imade H, Beno D et al: Synthesis and biological evaluation of heterocycle containing adamantane 11β-HSD1 inhibitors. Bioorg Med Chem Lett (2006) 16(20):5414-5419.
44. Patel JR, Shuai Q, Dinges J, Winn M, Pliushchev M, Fung S, Monzon K, Chiou W, Wang J, Pan L, Wagaw S et al: Discovery of adamantane ethers as inhibitors of 11β-HSD-1: Synthesis and biological evaluation. Bioorg Med Chem Lett (2007) 17(3):750-755.
45. Sorensen B, Winn M, Rohde J, Shuai Q, Wang J, Fung S, Monzon K, Chiou W, Stolarik D, Imade H, Pan L et al: Adamantane sulfone and sulfonamide 11-β-HSD1 inhibitors. Bioorg Med Chem Lett (2007) 17(2):527-532.
46. Yeh VS, Kurukulasuriya R, Madar D, Patel JR, Fung S, Monzon K, Chiou W, Wang J, Jacobson P, Sham HL, Link JT: Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements. Bioorg Med Chem Lett (2006) 16(20):5408-5413.
47. Yeh VS, Kurukulasuriya R, Kerdesky FA: A highly efficient synthesis of potent and selective butyrolactam inhibitors of 11β-HSD1. Org Lett (2006) 8(18):3963-3966.
48. Yeh VS, Kurukulasuriya R, Fung S, Monzon K, Chiou W, Wang J, Stolarik D, Imade H, Shapiro R, Knourek-Segel V, Bush E et al: Discovery of orally active butyrolactam 11β-HSD1 inhibitors. Bioorg Med Chem Lett (2006) 16(21):5555-5560.
49. Webster SP, Ward P, Binnie M, Craigie E, McConnell KMM, Sooy K, Vinter A, Seckl JR, Walker BR: Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors. Bioorg Med Chem Lett (2007) 17(10):2838-2843.
50. Richards S, Sorensen B, Jae HS, Winn M, Chen Y, Wang J, Fung S, Monzon K, Frevert EU, Jacobson P, Sham H et al: Discovery of potent and selective inhibitors of 11β-HSD1 for the treatment of metabolic syndrome. Bioorg Med Chem Lett (2006) 16(24):6241-6245.
51. Shah U, Boyle CD, Chackalamannil S, Baker H, Kowalski T, Zhang L, Terracina G: Novel analogs as 11β-HSD1 inhibitors. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 049.
52. Lankin CM, Boyle CD, Chackalamannil S, Shah U, Baker H, Kowalski T, Zhang L, Terracina G: Discovery and SAR of novel derivatives as 11β-hydroxysteroid dehydrogenase type 1 inhibitors. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 052.
53. Flyrén K, Bergquist LO, Castro VM, Fotsch C, Johansson L, St Jean DJ Jr, Sutin L, Williams M: Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Bioorg Med Chem Lett (2007) 17(12):3421-3425.
54. Neelamkavil SF, Boyle CD, Chackalamannil S, Baker H, Kowalski T, Zhang L, Terracina G: Synthesis and biologic evaluation of selective inhibitors of 11β-HSD1 as a potential treatment for metabolic disorders. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 053.
55. Zhuo J, Xu M, Zhang C, Qian D, Li Y, Huber R, Covington M, Marando C, Metcalf B, Yao W: Discovery and synthesis of nipecotic amide as novel, potent and selective 11β-HSD-1 inhibitors. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 048.
56. Li YL, Bostrom L, Zhuo J, Li Y, Covington M, Huber R, Metcalf B, Yao W: Syntheses and SAR of piperidin-3-yl ureas as potent and selective 11β-HSD-1 inhibitors. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 054.
57. Sun D, DeGraffenreid M, He X, Jaen J, Powers JP, Yan X, Di Y, Tu H, Ursu S, Ma J, Miao S et al: Discovery and optimization of arylsulfonamide as a novel class of 11β-HSD1 inhibitors. 234th American Chemical Society National Meeting, Boston, MA, USA (2007):MEDI 055.
58. Bhat BG, Hosea N, Fanjul A, Herrera J, Chapman J, Thalacker F, Stewart PM, Rejto PA: Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11β- hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther (2008) 324(1):299-305. • Describes the use of exogenous prednisone to prednisolone conversion as a biomarker for 11β-HSD1 inhibition.
59. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B: Modulation of 11β-hydroxysteroid dehydrogenase (11βHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11βHSD1 inhibitor. J Clin Endocrinol Metab (2008) 93(2):550-556. •• Describes the application of the prednisone/prednisolone biomarker (see reference [58•]) in human clinical trials of the selective 11β-HSD1 inhibitor PF-915275.
60. Xiang J, Ipek M, Suri V, Tam M, Xing Y, Huang N, Zhang Y, Tobin J, Mansour TS, McKew J: β-Keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type 1 and the mechanism of action. Bioorg Med Chem (2007) 15(13):4396-4405.
61. Ipek J, Xiang J, Chen L, Huang N, Li J, Li W, Mansour T, McKew JC, Nunez J, Suri V, May T et al: β-Keto sulfonamides as selective inhibitors of the 11β-HSD1. 234th American Chemical Society National Meeting, Boston, MA, USA (2007): MEDI 050.
62. A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks: US National Library of Medicine, Bethesda, MD, USA (2008). www.clinicaltrials.gov/ct2/show/NCT00427401?term=PF- 00915275&rank=1
63. BVT-3498. Thomson Pharma Drug Report, Thomson Reuters - Scientific, London, UK (2008).
64. Pipeline: Amgen Inc, Thousand Oaks, CA, USA (2008). wwwext.amgen.com/science/pipe.jsp
65. Incyte Corp: Incyte reports progress in multiple clinical programs; expands JAK inhibitor program; announces 2007 financial results and provides 2008 financial guidance. Press Release (2008) February 14.
66. INCB-13739. Thomson Pharma Drug Report, Thomson Reuters - Scientific, London, UK (2008).
67. Incyte's Product Pipeline: Incyte Corp, Wilmington, DE, USA (2008). www.incyte.com/drugs_product_pipeline.html
68. Pahan K: Lipid-lowering drugs. Cell Mol Life Sci (2006) 63(10):1165-1178.
69. Ashiya M, Smith RET: Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov (2007) 6(10):777-778.
70. MIRIAM HOSPITAL/POPULATION COUNCIL (Morris DJ, Latif SA, Hardy MP, Ge R): Selective testicular 11β-HSD inhibitors for the treatment of hypergonadism associated disorders and modulation of fertility. US-20070219172 (2007).
71. TAISHO PHARMACEUTICAL CO LTD (Fukushima H, Takahashi M, Mikami A, Busujima T, Kawaguchi T, Hirano H): Thiazole derivative. WO-2006051662 (2006).
72. TAKEDA SAN DIEGO INC (Brennan NK, Chang E, Kaldor SW, Kiryanov AA, Jennings AJ, Stafford JA): Hydroxysteroid dehydrogenase inhibitors. WO-2006066109 (2006).
73. HOFFMANN-LA ROCHE INC (Gillespie P, Goodnow RA, Kowalczyk A, Le K, Zhang Q): Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase. US-20070167622 (2007).
74. ONO PHARMACEUTICAL CO LTD (Egashira H, Nishiyama E): Sulfonamide compound and pharmaceutical thereof. WO-2006095822 (2006).
75. AMGEN INC/BIOVITRUM AB (Henriksson M, Homan E, Johansson L, Vallgarda J, Williams M, Bercot EA, Fotsch CH, Li A, Cai G, Hungate RW, Yuan CC et al): Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1. WO-2007061661 (2007).
76. AMGEN INC (Bunel E, Guram A, Liu Q): Catalyzed process of making C-5-substituted heterocyclic inhibitors of 11β-hydroxy steroid dehydrogenase type 1. US-20070117985 (2007).
77. HOFFMANN-LA ROCHE INC (Banner BL, Bilotta JA, Fotouhi N, Gillespie P, Goodnow RA Jr, Hamilton MM, Haynes NE, Kowalczyk A, Mayweg A, Myers MP, Pietranico-Cole SL et al): Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase. US-20070049632 (2007).
78. HOFFMANN-LA ROCHE INC (Amrein K, Hunziker D, Kuhn B, Mayweg AV, Neidhart W): New pyrazolones as 11β-HSD1 inhibitors for diabetes. US-20070049574 (2007).
79. ASTELLAS PHARMA INC (Murakami T, Kawano T, Shiraki R, Ishii H, Yoshimura S, Ohkawa T, Hosaka M, Fukudome H, Inoki Y): Triazole derivative or salt thereof. WO-2006030805 (2006).
80. ASTELLAS PHARMA INC (Yoshimura S, Shiraki R, Kawano T, Susuga D, Hosaka M, Fukudome H, Kurosawa K, Ishii H, Koike T): Triazole derivative or salt thereof. WO-2007105753 (2007).
81. BRISTOL-MYERS SQUIBB CO (Li J, Hamann LG, Wang H): Heteroaryl 11-β-hydroxysteroid dehydrogenase type 1 inhibitors. US-20060281750 (2006).
82. BRISTOL-MYERS SQUIBB CO (Li J, Robl JA, Kennedy LJ): Triazine 11-β hydroxysteroid dehydrogenase type 1 inhibitors. US-20070207985 (2007).
83. BRISTOL-MYERS SQUIBB CO (Robl JA, Wu SC, Yoon DS): Pyridone/ hydroxypyridine 11-β hydroxysteroid dehydrogenase type 1 inhibitors. WO-2008005910 (2008).
84. F HOFFMANN-LA ROCHE AG (Amrein K, Hunziker D, Kuhn B, Mayweg AV, Neidhart W): Pyridazine derivatives. WO-2007003521 (2007).
85. F HOFFMANN-LA ROCHE AG (Amrein K, Hunziker D, Kuhn B, Mayweg AV, Neidhart W): Alkyl-pyridazine derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase type 1 (11β-HSD 1). WO-2008003611 (2008).
86. ELI LILLY AND CO (Aicher TD, Chicarelli MJ, Hinklin RJ, Tian H, Wallace OB): Cycloalkyl lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2006068991 (2006).
87. ELI LILLY AND CO (Aicher TD, Chicarelli MJ, Gauthier CA, Hinklin RJ, Tian H, Wallace OB, Krasutsky AP, Allen JG): Cycloalkyl lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2006068992 (2006).
88. ELI LILLY AND CO (Aicher TD, Chen Z, Hinklin RJ, Hite GA, Krasutsky AP, Li R, McCowan JR, Saeed A, Snyder NJ, Toth JL, Wallace OB et al): Biphenyl amide lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007124337 (2007).
89. ELI LILLY AND CO (Allen JG, Krasutsky AP, Wallace OB, Xu Y, York JS): Substituted pyrrolidinones as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007127693 (2007).
90. ELI LILLY AND CO (Li R, Wallace OB, Xu Y): Inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007127765 (2007).
91. ELI LILLY AND CO (Bush JK, Hansen MM, Li R, Mabry TE, Snyder NJ, Wallace OB, Xu Y): Inhibitors of 11-β- hydroxysteroid dehydrogenase 1. WO-2007127688 (2007).
92. ELI LILLY AND CO (York JS, Wallace OB, Xu Y): Piperidinyl substituted pyrrolidinones as inhibitors of 11-β- hydroxysteroid dehydrogenase 1. WO-2007127901 (2007).
93. ELI LILLY AND CO (Guenther RL, Mabry TE, Saeed A, Snyder NJ, Wallace OB, Xu Y): Cyclohexylimidazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007124329 (2007).
94. ELI LILLY AND CO (Aicher TD, Anzeveno PB, Li R, Krasutsky AP, Mabry TE, Saeed A, Snyder NJ, Stephenson GA, Tian H, Wallace OB, Winneroski LL Jr et al): Cyclohexylpyrazole lactam derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007124254 (2007).
95. ELI LILLY AND CO (Krasutsky AP, Snyder NJ, Wallace OB, Xu Y, York JS): Cyclohexyl substituted pyrrolidinones as inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007127704 (2007).
96. ELI LILLY AND CO (Wallace OB, Li R, Mabry TE, Winneroski LL Jr, Xu Y): Inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007127726 (2007).
97. ELI LILLY AND CO (Winneroski LL Jr, Mabry TE, Snyder NJ, Wallace OB, Xu Y): Inhibitors of 11-β-hydroxysteroid dehydrogenase 1. WO-2007127763 (2007).
98. ABBOTT LABORATORIES (Yeh VS, Kurukulassuriya R, Madar DJ, Link JT): Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme. WO-2007118185 (2007).
99. TAKEDA PHARMACEUTICAL CO LTD (Cho N, Kasai S, Yamashita T): Prophylactic/therapeutic agent for diabetes. WO-2006104280 (2006).
100. TAISHO PHARMACEUTICAL CO LTD (Fukushima H, Takahashi H, Mikami A, Tanaka H): Preparation of imidazolidinone derivatives as 11β-HSD1 inhibitors. JP-2007254409 (2007).
101. SHIONOGI AND CO LTD (Ogawa T, Kurose N, Tanaka S, Nishi K): Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity. WO-2006132197 (2006).
102. SHIONOGI AND CO LTD (Ogawa T, Chomei N, Masuda K, Tanaka S): Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1. WO-2007114124 (2007).
103. SHIONOGI AND CO LTD (Kurose N, Hayashi M, Ogawa T, Masuda K, Kojima E): Heterocyclic compound having inhibitory activity on 11-β-hydroxysteroid dehydrogenase type 1. WO-2007058346 (2007).
104. F HOFFMANN-LA ROCHE AG (Anderson KW, Fotouhi N, Gillespie P, Goodnow RA Jr, Guertin KR, Haynes NE, Myers MP, Pietranico-Cole SL, Qi L, Rossman PL, Scott NR et al): Pyrazoles as 11-β-HSD-1. WO-2007107470 (2007).
105. PFIZER PRODUCTS INC (Cheng H, Cripps SJ, Lafontaine JA, Le PTQ, Matthews JJ, Nair SK): Sulfonyl derivatives. WO-2007057768 (2007).
106. MERCK PATENT GMBH (Carniato D, Charon C, Gleitz J, Roche D, Hock B): 2-Adamantylurea derivatives as selective 11β-HSD1 inhibitors. WO-2007068330 (2007).
107. VITAE PHARMACEUTICALS INC (Claremon DA, Singh SB, Tice CM, Ye Y, Cacatian S, He W, Simpson R, Xu Z, Zhao W): Inhibitors of 11β-hydroxysteroid dehydrogenase type 1. WO-2008024497 (2008).
108. NOVO NORDISK A/S (Ebdrup S): Adamantane derivatives for the treatment of metabolic syndrome. WO-2007107550 (2007).
109. BRISTOL-MYERS SQUIBB CO (Ye XY, Robl JA, Hanson RL, Guo Z, Patel RN): Cyclic 11-β hydroxysteroid dehydrogenase type 1 inhibitors. WO-2008024892 (2008).
110. NOVO NORDISK A/S (Ebdrup S, Andersen HS): 4-Piperidylbenzamides as 11-β-hydroxysteroid dehydrogenase type 1 inhibitors. WO-2008006703 (2008).
111. NOVO NORDISK A/S (Ebdrup S, Andersen HS): 11β-hydroxysteroid dehydrogenase type 1 active compounds. WO-2008006702 (2008).
112. NOVO NORDISK A/S (Ebdrup S, Andersen HS): 11β-Hydroxysteroid dehydrogenase type 1 active compounds. WO-2007115935 (2007).
113. HOFFMANN-LA ROCHE INC (Gillespie P, Goodnow RA Jr, Zhang Q): Pyrazoles. US-20060223852 (2006).
114. INCYTE CORP (Yao W, Xu M, Zhang C, Agrios K, Metcalf B, Zhuo J): Amido compounds and their use as pharmaceuticals. WO-2006002349 (2006).
115. INCYTE CORP (Zhuo J, Li YL, Xu M, He C, Yao W): Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same. US-20070208001 (2007).
116. INCYTE CORP (Li YL, Yao W): Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same. WO-2007101270 (2007).
117. INCYTE CORP (Li YL, Bostrom LL, Yao W): Tetrasubstituted ureas as modulators of 11-β hydroxyl steroid dehydrogenase type 1. WO-2007130898 (2007).
118. AMGEN INC/BIOVITRUM AB (Fotsch CH, Bartberger MD, Haraldsson M, St Jean D, Johansson L, Nilsson M, Sutin L): Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1. WO-2008011453 (2008).
119. SANOFI-AVENTIS (Braun A, Gussregen S, Mougenot P, Namane C, Nicolai E, Pacquet F, Philippo C, Venier O, Crespin O, Pascal C, Aletru M): Derivatives of ureas of piperidine or pyrrolidine, their preparation and their therapeutical use. WO-2008000950 (2008).
120. INCYTE CORP (Yao W, Xu M, Zhang C, Li Y, Zhuo J, Metcalf BW): N-Substituted piperidines and their use as pharmaceuticals. US-20060004049 (2006).
121. HOFFMANN-LA ROCHE INC (Gillespie P, Goodnow RA Jr, Kowalczyk A, So SS, Zhang Q): Aryl sulfonyl piperidines. US-20060199816 (2006).
122. NOVO NORDISK A/S (Kilburn JP, Kampen GCT, Andersen HS): Pharmaceutical use of substituted piperidine carboxamides. WO-2007144394 (2007).
123. ASTRAZENECA PLC (McCoull W, Packer M, Scott JS, Whittamore PRO): Chemical compounds 428. WO-2008012532 (2008).
124. WYETH (Xiang JS, Saiah E, Tam SY, McKew JC, Chen L, Ipek M, Lee K, Li HQ, Li J, Li W, Mansour TS et al): 11-β HSD1 inhibitors. WO-2007092435 (2007).
125. TAKEDA SAN DIEGO INC (Aertgeerts K, Brennan NK, Cao SX, Chang E, Kiryanov AA, Liu Y): Hydroxysteroid dehydrogenase inhibitors. WO-2006105127 (2006).
126. AMGEN INC (Powers JP, DeGraffenreid MR, He X, Julian L, McMinn DL, Sun D, Rew Y, Yan X): Benzamide derivatives and uses related thereto. WO-2006138508 (2006).
127. AMGEN INC (Powers JP, Rew Y, Yan X): Benzamide derivatives and uses related thereto. WO-2007145834 (2007).
128. ASTRAZENECA AB (Caulkett PWR, McCoull W, Packer M, Whittamore PRO): 1,4-Disubstituted piperazine and 1,4-disubstituted azepane as 11-β-hydroxysteroid dehydrogenase 1 inhibitors. WO-2007135427 (2007).
129. ASTRAZENECA PLC (Caulkett PWR, McCoull W, Packer M, Whittamore PRO): Diazepan-1-yl-sulfonyl derivatives for the treatment of metabolic syndrome. WO-2007122411 (2007).
130. HOFFMANN-LA ROCHE INC (Amrein K, Hunziker D, Kuhn B, Mayweg A, Neidhart W): Pyridines. US-20060074237 (2006).
131. AMGEN INC (Powers JP, He X, McMinn D, Rew Y): Aniline sulfonamide derivatives and their uses. US-20070021502 (2007).